

Page 2 - Mr. Benjamin Gordon

I also informed Dr. DuPont and Mr. Bensinger that FDA plans to discuss appropriate treatment of hyperkinesis and narcolepsy with our Neurology Advisory Committee on February 3, 1977. That committee will provide us with expert advice on the current state-of-the-art in this area.


I also explained our proposed administrative approach to any regulatory action. In short, for those drugs which are associated with the greatest drug abuse, we will develop a Notice of Opportunity for a Hearing that will be published in the Federal Register. Our current target date for such a Notice is March 1977. We anticipate a hearing would be requested and, if so, this would prolong any final action by a number of months.

We also discussed the possibility of rescheduling the anorectics should the data suggest that this is appropriate. DEA has been developing information on the level of abuse of phenmetrazine as well as the Schedule III and IV anorectics for some time and expects to report their findings to us within several months.

I am pleased with progress to date and consider the work by our respective staffs to be on schedule.

Best wishes for the New Year.

Sincerely yours,


J. Richard Crout, M.D.
Director
Bureau of Drugs